|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 22.01 Million
|
|
Market Size (2030)
|
USD 33.45 Million
|
|
CAGR (2025-2030)
|
7.89%
|
|
Fastest Growing Segment
|
Diagnostics And Screening
|
|
Largest Market
|
North
|
Market Overview
Oncology NGS Market in India was valued at USD 22.01 million in 2024 and is anticipated to reach USD 33.45 Million by 2030, with a CAGR of 7.89% during forecast period.
The India Oncology NGS (Next-Generation Sequencing) Market is a rapidly
evolving segment of the country's healthcare industry, marked by the
intersection of cutting-edge genomic technologies and the critical need for
advanced cancer diagnostics and treatments. This market encompasses the
application of NGS techniques in the field of oncology, primarily for the
profiling of cancer genomes, identifying mutations, and guiding personalized
therapeutic interventions.
In
recent years, the India Oncology NGS Market has experienced significant growth
due to several key factors. First and foremost, the rising incidence of cancer
in India, attributed to various factors such as lifestyle changes, pollution,
and an aging population, has created a pressing demand for more precise and
efficient cancer diagnosis and treatment methods. Next-Generation Sequencing
offers an unprecedented level of genomic insights, enabling oncologists to
tailor treatment strategies based on an individual's genetic makeup.
Increased awareness of the potential benefits of NGS in oncology, coupled with
government initiatives and healthcare investments, has fostered a favorable
environment for market expansion. The emergence of private sector players,
diagnostic laboratories, and collaborations between research institutions and
pharmaceutical companies has driven technological advancements and the
availability of NGS-based cancer diagnostic tests across the country.
The
India Oncology NGS Market is characterized by a wide range of applications,
including mutation profiling, liquid biopsy, and minimal residual disease
monitoring, to name a few. As precision medicine gains momentum, NGS is playing
a pivotal role in helping oncologists choose the most effective therapies for
patients, reducing the trial-and-error approach often associated with cancer
treatment.
Key Report Takeaway
- Whole Exome Sequencing led by technology in 2024, focusing on exon regions where most cancer related mutations are concentrated
- Strong clinical value in oncology genomic profiling supported identification of actionable mutations and targeted therapy selection
- Cost advantage over Whole Genome Sequencing improved accessibility, as WES analyzes key coding regions while limiting excessive data generation
- North India dominated regionally, supported by advanced oncology centers such as All India Institute of Medical Sciences in Delhi and Post Graduate Institute of Medical Education and Research in Chandigarh
Key Market Drivers
Rising Incidence of Cancer
The rising incidence of cancer in India is undeniably one of the primary drivers behind the booming India Oncology Next-Generation Sequencing (NGS) market. Over the past few decades, the country has witnessed a significant surge in cancer cases, creating an urgent need for advanced diagnostic and treatment strategies. Multiple factors contribute to this escalating cancer burden, including lifestyle changes, increased pollution levels, and an aging population. In 2022, India recorded an estimated 1,413,316 new cancer cases and 916,827 cancer deaths, as reported in the GLOBOCAN 2022 India fact sheet.
According to the World Cancer Research Fund, India is projected to experience an annual increase of approximately 12% in cancer cases, and cancer is on track to become the leading cause of mortality in the country. These alarming statistics underline the pressing demand for more sophisticated and efficient tools to detect and combat cancer effectively. India’s National Cancer Registry Programme estimates 14,61,427 incident cancer cases in 2022 and projects the incidence to rise to 15,69,793 by 2025.
NGS technology has emerged as a critical solution to address this challenge. By enabling comprehensive genomic profiling of cancer patients, NGS empowers healthcare providers to gain a deeper understanding of the genetic underpinnings of the disease. This not only allows for early and accurate cancer diagnosis but also facilitates the identification of specific genetic mutations and alterations within tumors. To support more consistent clinical use, the Indian Society of Medical and Pediatric Oncology developed consensus guidelines to standardize quality assurance and reporting for oncology NGS tests in India.
The ability to personalize treatment approaches based on a patient's unique genetic profile is a game-changer in cancer care. This approach, known as precision medicine, helps oncologists select the most appropriate and targeted therapies, improving treatment efficacy and minimizing side effects. The rising incidence of cancer underscores the importance of implementing precision medicine, further driving the demand for NGS technologies in the Indian healthcare system. The Government-supported National Cancer Grid, funded by the Department of Atomic Energy, is a network of over 380 cancer centres and affiliated organizations and reports that its member institutions treat over 860,000 new cancer patients annually, helping scale standardized, evidence-based oncology care that increasingly incorporates molecular testing.
Advancements in NGS Technology
Advancements
in Next-Generation Sequencing (NGS) technology have been a pivotal driver in
propelling the India Oncology NGS Market to new heights. These technological
innovations have not only made NGS more accessible and cost-effective but have
also significantly improved its accuracy, speed, and versatility, which are
vital in the field of oncology.
One
of the most notable advancements in NGS technology is the development of
high-throughput sequencing platforms. These platforms can process a large
volume of genetic data in a relatively short time, making it feasible to
analyze numerous samples simultaneously. In the context of oncology, this means
faster and more efficient genomic profiling of cancer patients, allowing
healthcare providers to make timely decisions regarding diagnosis and
treatment. The speed at which NGS can generate results is particularly critical
in cancer cases, where timely intervention can be life-saving.
The advancements in NGS technology have led to cost reductions, making it more
accessible to a broader segment of the Indian population. The decreasing cost
of sequencing has made it economically viable for diagnostic laboratories,
research institutions, and even smaller healthcare facilities to adopt NGS
technology. This democratization of NGS has expanded its reach and led to a
wider adoption in the field of oncology.
Another
significant advancement is the development of user-friendly and streamlined NGS
workflows. These innovations have simplified the process of genomic sequencing
and data analysis, making it more accessible to laboratories with varying
levels of expertise. With more intuitive software interfaces and reduced
hands-on requirements, NGS has become a practical tool for a broader range of
healthcare professionals. This has enabled the efficient integration of NGS
into routine clinical practice, including oncology.
Moreover,
the accuracy of NGS technology has improved significantly. Reduced error rates
in sequencing and data analysis have enhanced the reliability of NGS results.
In the context of oncology, where the identification of specific genetic
mutations and alterations in tumors is crucial for personalized treatment, this
heightened accuracy is a game-changer. Healthcare providers can now trust NGS
results to guide them in selecting the most appropriate targeted therapies and
treatment strategies for individual cancer patients.
Download Free Sample Report
Key Market Challenges
High Costs and Limited
Accessibility
The
India Oncology NGS (Next-Generation Sequencing) Market holds immense promise in
revolutionizing cancer diagnosis and treatment. However, a significant hurdle
that has impeded its widespread adoption is the high costs associated with NGS
technology and the resulting limited accessibility. The expense of NGS-based
services creates disparities in access to advanced cancer diagnostics and
personalized treatments, affecting the equitable provision of healthcare
services across the country.
NGS
is a sophisticated and resource-intensive technology, involving expensive
equipment, specialized laboratories, and skilled personnel. While advancements
have made NGS more cost-effective over the years, it still remains relatively
expensive, particularly when compared to conventional diagnostic methods. As a
result, many patients, especially those in underprivileged or rural areas, face
financial barriers to accessing NGS-based cancer diagnostics and therapies.
The
lack of accessibility is further exacerbated by the concentration of advanced
healthcare facilities in urban and metropolitan areas. Many rural regions in
India lack the necessary infrastructure and expertise to offer NGS services.
This geographical disparity in healthcare access means that patients in remote
areas often have limited or no access to NGS technology, despite the potential
benefits it offers in terms of early and accurate cancer diagnosis and
personalized treatment.
Insurance
coverage in India presents another challenge. While a significant portion of
the Indian population relies on public and private health insurance, many
insurance providers do not include NGS-based tests and treatments in their
coverage, or they may have limited reimbursement policies. This places a
substantial financial burden on patients who are already grappling with the
high costs of cancer care, which can be financially crippling for many
families.
Lack of Standardization
The
India Oncology NGS (Next-Generation Sequencing) Market has been marked by
remarkable advancements in genomics and the promise of personalized cancer
care. However, a significant obstacle that hinders the full realization of its
potential is the lack of standardization. Without standardized protocols and
guidelines for NGS in oncology, variability in methodologies and data analysis
can lead to inconsistencies in results, affecting the reliability and
comparability of NGS-based tests.
NGS
technology encompasses a diverse array of platforms, reagents, and workflows,
often tailored to specific laboratory settings and research purposes. This
inherent flexibility is advantageous in many respects but also poses
challenges, particularly in the context of clinical diagnostics. The lack of
standardized procedures can result in variability in the quality and accuracy
of NGS-based tests, making it challenging to ensure consistent and reproducible
results across different laboratories and institutions.
Standardization
is crucial in oncology, where the stakes are high, and the accuracy of
diagnostic and treatment decisions can have a profound impact on patient
outcomes. Without standardized procedures, oncologists and other healthcare
providers may face difficulties in interpreting NGS results and confidently
basing treatment decisions on them. Inconsistent methodologies can lead to
confusion and uncertainty in the clinical setting, reducing trust in NGS as a
reliable tool in oncology.
Key Market Trends
Promising Clinical Trials and
Drug Development
One
of the most significant trends propelling the India Oncology NGS
(Next-Generation Sequencing) Market is the promising landscape of clinical
trials and drug development. NGS technology has become a driving force in these
domains, contributing to the advancement of cancer research, the development of
targeted therapies, and the expansion of clinical trials that offer new hope to
cancer patients.
NGS
technology's ability to identify specific genetic mutations and alterations
within tumors has transformed the way clinical trials are conducted in the
field of oncology. By precisely characterizing the genetic profiles of patients
and their tumors, NGS allows researchers to select suitable patient populations
for clinical trials, ensuring that the treatments are more likely to be
effective. This targeted approach not only enhances the chances of success in
clinical trials but also reduces the exposure of patients to potentially
ineffective treatments, minimizing unnecessary side effects and costs.
Moreover,
NGS enables the discovery of therapeutic targets and biomarkers, facilitating
the development of highly specific and personalized cancer therapies. This
trend has redefined drug development by shifting the focus from traditional
one-size-fits-all treatments to precisely tailored approaches. In India, this
transformation is particularly promising, as it means that cancer patients have
access to treatments that are more effective and have fewer side effects.
As
a result of these developments, the landscape of clinical trials in India has
evolved significantly. More trials are now designed to target specific genetic
alterations, allowing for the evaluation of novel therapeutic agents and
regimens. The integration of NGS technology into clinical trial design and
patient selection has expedited the development of breakthrough therapies that
have the potential to revolutionize cancer care in the country.
Diverse Applications of NGS in
Oncology
The diverse applications of Next-Generation Sequencing (NGS) technology in oncology have been instrumental in propelling the India Oncology NGS Market to new heights. NGS is not limited to a singular purpose; rather, it offers a versatile set of tools that can be applied in various facets of cancer diagnosis, treatment, and research, making it an invaluable asset in the fight against cancer. In 2022, India recorded an estimated 1,413,316 new cancer cases and 916,827 cancer deaths, reinforcing the need for scalable, information-rich oncology testing approaches such as NGS.
NGS's adaptability in oncology is evident through its multitude of applications, including mutation profiling, liquid biopsy, minimal residual disease monitoring, and the identification of therapeutic targets. Mutation profiling allows healthcare providers to comprehensively analyze the genetic alterations in a patient's tumor, helping them select the most suitable treatment options. This approach is particularly essential in the era of precision medicine, where therapies are tailored to the specific genetic makeup of the patient and their cancer. In India, the Indian Society of Medical and Pediatric Oncology has issued consensus guidance on uniform reporting of oncology NGS to improve test quality and clinical interpretability.
Liquid biopsy is another groundbreaking application of NGS that allows for the non-invasive detection of cancer-related genetic alterations in blood or other bodily fluids. It enables early cancer detection, monitoring of disease progression, and the assessment of treatment response, all without the need for invasive procedures. This minimizes patient discomfort and contributes to early intervention. The Government-supported National Cancer Grid is a network of over 380 cancer centres and affiliated organizations, indicating a large national clinical ecosystem where less invasive, repeatable monitoring approaches can be operationalized at scale.
NGS also plays a crucial role in minimal residual disease monitoring, allowing healthcare providers to detect and track the presence of residual cancer cells after treatment. This is vital in assessing the effectiveness of therapy, predicting relapses, and making informed decisions regarding ongoing treatment strategies. India’s National Cancer Registry Programme projects incident cancer cases to rise to 15,69,793 by 2025, which increases the need for post-treatment surveillance tools that can support relapse-risk stratification.
Identifying therapeutic targets is yet another application where NGS shines. By analyzing the genetic profile of a patient's tumor, NGS can pinpoint specific genetic alterations that can be targeted with precision therapies, such as targeted inhibitors or immunotherapies. This application ensures that cancer patients receive the most effective and individualized treatments available. The National Cancer Grid is funded by the Department of Atomic Energy, reflecting sustained public-sector backing for standardized, evidence-based oncology pathways that increasingly depend on molecular characterization.
Segmental Insights
Technology Insights
Based on the Technology, Whole Exome Sequencing (WES) emerged
as the dominant segment in the market for India Oncology NGS Market
in 2024.
WES
is highly relevant in the context of oncology. It captures the genetic
alterations within the exons of the genes, where many cancer-related mutations
are concentrated. This focused approach is particularly valuable in identifying
actionable mutations and therapeutic targets specific to cancer, making it the
preferred choice for cancer genomic profiling. Whole Genome Sequencing (WGS)
offers a complete genomic analysis, including both coding and non-coding
regions, but it is substantially more expensive and generates a vast amount of
data. In contrast, WES provides a cost-effective alternative, concentrating on
the most biologically relevant portions of the genome. This cost-efficiency
makes it a practical choice for widespread adoption in the India Oncology NGS
Market, where cost considerations are significant.
Download Free Sample Report
Regional Insights
North region emerged as the dominated in the India Oncology NGS Market in 2024, holding the largest market
share. The northern region of India, which
includes major cities like Delhi, NCR (National Capital Region), and
Chandigarh, boasts advanced healthcare infrastructure and facilities. The
northern region is renowned for hosting some of India's most prestigious
healthcare institutions, including All India Institute of Medical Sciences
(AIIMS) in Delhi and Post Graduate Institute of Medical Education and Research
(PGIMER) in Chandigarh. These institutions are at the forefront of research and
clinical practice in oncology, and they have played a pivotal role in driving
the adoption of NGS for cancer diagnosis and personalized treatment.
Recent Developments
- In February 2026, Gene Solutions and Global Cancer Care (GCC) highlighted SPOT‑MAS in India as an AI-enabled, multi-omics ctDNA blood test positioned for multi-cancer early detection and tumor-location prediction support.
- In February 2026, MedGenome highlighted TumorTrack Advance as a tissue-biopsy based comprehensive genomic profiling (CGP) oncology NGS assay covering 500+ genes and signatures such as SNVs/Indels/CNVs/fusions plus TMB, MSI, and HRD for solid tumors.
- In November 2025, MedGenome announced a majority investment in Green Cross Genetics Lab to expand its genomics-led diagnostics footprint across India by combining Green Cross’s diagnostics network with MedGenome’s genomics capabilities.
Key Market Players
|
By Technology
|
By Application
|
By Region
|
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted & Gene Panel Sequencing
|
- Diagnostics and Screening
- Companion Diagnostics
- Other Diagnostics
|
|
Report Scope:
In this report, the India Oncology NGS Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- India Oncology NGS Market, By Technology:
o Whole Genome Sequencing
o Whole Exome Sequencing
o Targeted & Gene Panel Sequencing
- India Oncology NGS Market, By Application:
o Diagnostics and Screening
o Companion Diagnostics
o Other Diagnostics
- India Oncology NGS Market, By Region:
o North
o East
o West
o South
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the India Oncology
NGS Market.
Available Customizations:
India Oncology NGS Market report with the given market data, TechSci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
India Oncology NGS Market is an upcoming report to
be released soon. If you wish an early delivery of this report or want to
confirm the date of release, please contact us at [email protected]